Search results
Results from the WOW.Com Content Network
The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit. Shield is indicated for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older.
In July, the Food and Drug Administration (FDA) approved the first blood test to use as primary screening for people at average risk for colon cancer. Called Shield, the test looks for the presence of specific changes to DNA floating freely in the blood, called cell-free DNA, that indicate the presence of a tumor or precancerous growths in the ...
The US Food and Drug Administration has approved the company Guardant Health’s Shield blood test for colorectal cancer screening in adults, 45 and older, who are at average risk for the...
The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to screen for colon cancer. The test isn't meant to replace colonoscopies, but is generating ...
The FDA has approved a new colorectal cancer blood test by Guardant Health for Medicare coverage. The test, called Shield, looks for “free-floating” fragments of cancer DNA in the...
On May 23, the U.S. Food and Drug Administration (FDA)’s Medical Devices Advisory Committee strongly recommended FDA approval of the Guardant Health blood test for colorectal cancer (CRC) screening, Shield™.
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage. Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates.
You can now screen at any healthcare visit with Shield, the first FDA-approved blood test for colon cancer covered by Medicare. Request Shield.
Shield is a blood-based test that detects colorectal cancer with high accuracy. The test uses a multimodal approach, integrating genomics, epigenomics and proteomics, to detect colorectal cancer signals in the bloodstream, including DNA that is shed by tumors, called circulating tumor DNA (ctDNA).
The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit. Shield is indicated for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older.